Cargando…

Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation

Detalles Bibliográficos
Autor principal:	Kamen, Amine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310064/ https://www.ncbi.nlm.nih.gov/pubmed/34358139 http://dx.doi.org/10.3390/vaccines9070722

Ejemplares similares

Vero cell upstream bioprocess development for the production of viral vectors and vaccines
por: Kiesslich, Sascha, et al.
Publicado: (2020)

Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use
por: Fulber, Julia P. C., et al.
Publicado: (2022)

Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa
por: Farnós, Omar, et al.
Publicado: (2020)

The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response
por: Kapnick, Senta M.
Publicado: (2022)

The rapid progress in COVID vaccine development and implementation
por: Barrett, Alan D. T., et al.
Publicado: (2022)

The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World
por: Greenhawt, Matthew, et al.
Publicado: (2021)

Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
por: Sayedahmed, Ekramy E., et al.
Publicado: (2020)

Critical Assessment of Purification and Analytical Technologies for Enveloped Viral Vector and Vaccine Processing and Their Current Limitations in Resolving Co-Expressed Extracellular Vesicles
por: Do Minh, Aline, et al.
Publicado: (2021)

Process Development for Newcastle Disease Virus-Vectored Vaccines in Serum-Free Vero Cell Suspension Cultures
por: Fulber, Julia Puppin Chaves, et al.
Publicado: (2021)

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
por: Mendonça, Samir Andrade, et al.
Publicado: (2021)

Vaccination against COVID-19 and inequalities – Avoiding making a bad situation worse
por: Black, Michelle, et al.
Publicado: (2021)

Development of an adenovirus vector vaccine platform for targeting dendritic cells
por: Sharma, Piyush K, et al.
Publicado: (2017)

Calling for rapid development of a safe and effective MERS vaccine
por: Hotez, Peter J., et al.
Publicado: (2014)

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine
por: Yang, Zeyu, et al.
Publicado: (2023)

COVID-19 vaccines & pandemic
por: Bhatia, Rajesh, et al.
Publicado: (2021)

Immunization stress-related responses: Implications for vaccination hesitancy and vaccination processes during the COVID-19 pandemic
por: Taylor, Steven, et al.
Publicado: (2021)

An autotransporter display platform for the development of multivalent recombinant bacterial vector vaccines
por: Jong, Wouter SP, et al.
Publicado: (2014)

Situation analysis and an insight into assessment of pandemic COVID-19
por: Mansuri, Farah M.A.
Publicado: (2020)

COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
por: Ashraf, Muhammad Umer, et al.
Publicado: (2021)

Viral Vector Vaccines Are Victorious Against COVID-19 in Patients with Cirrhosis
por: Ferreira, Raphaella D., et al.
Publicado: (2022)

Viral Vector Vaccine Development and Application during the COVID-19 Pandemic
por: Deng, Shaofeng, et al.
Publicado: (2022)

Rapid development and deployment of high‐volume vaccines for pandemic response
por: Kis, Zoltán, et al.
Publicado: (2020)

(Healing) Philippines’ Situation amid Pandemic through Government Responsiveness in Securing COVID-19 Vaccine
por: Pacaol, Niñoval F.
Publicado: (2021)

Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
por: Chavda, Vivek P., et al.
Publicado: (2023)

Is it safe to vaccinate rheumatic immunosuppressed patients? Yes, of course, but how?
por: Gillet, Pierre
Publicado: (2021)

Current and Emerging Cell Culture Manufacturing Technologies for Influenza Vaccines
por: Milián, Ernest, et al.
Publicado: (2015)

Arenaviral vaccine vectors to combat infectious diseases
por: Dhanwani, Rekha, et al.
Publicado: (2016)

Coordinating COVID-19 vaccine deployment through the WHO COVID-19 Partners Platform
por: Yu, M Anne, et al.
Publicado: (2021)

Pandemic-response adenoviral vector and RNA vaccine manufacturing
por: Kis, Zoltán, et al.
Publicado: (2022)

The story behind Chile's rapid rollout of COVID-19 vaccination
por: Aguilera, Ximena, et al.
Publicado: (2021)

Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
por: Messina, Nicole L., et al.
Publicado: (2023)

Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
por: Alasandro, Mark, et al.
Publicado: (2021)

COVID-19 vaccines: the pandemic will not end overnight
por: The Lancet Microbe
Publicado: (2021)

Immune Response of the Host and Vaccine Development
por: Długosz, Ewa, et al.
Publicado: (2023)

The Improbability of the Rapid Development of a Vaccine for SARS-CoV-2
por: Morris, Kevin V.
Publicado: (2020)

Development of a novel glycoengineering platform for the rapid production of conjugate vaccines
por: Abouelhadid, Sherif, et al.
Publicado: (2023)

Rapid In-Process Monitoring of Lentiviral Vector Particles by High-Performance Liquid Chromatography
por: Transfiguracion, Julia, et al.
Publicado: (2020)

Viral Vectors for COVID-19 Vaccine Development
por: Lundstrom, Kenneth
Publicado: (2021)

The Covid-19 Vaccine-Development Multiverse
por: Heaton, Penny M.
Publicado: (2020)

COVID-19 vaccine candidates and vaccine development platforms available worldwide
por: Duman, Nilgun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i1l9qie91ka6po6kr6l58sv0o5